CD19 and Miyoshi myopathy: The impressive clinical results obtained in patients with B cell malignancies with the infusion of T cells genetically modified to express synthetic chimeric antigen receptors (CARs) against the lineage-specific surface antigen CD19 represented a turning point in the history of cancer immunotherapy (230–236) Intriguingly, T cells engineered with an anti-CD19 CAR were capable to induce complete remission also in a patient with MM.